Literature DB >> 28215250

Prevalence and quality of life and sleep in children and adolescents with restless legs syndrome/Willis-Ekbom disease.

Heidi Haueisen Sander1, Alan Luiz Eckeli2, Afonso Diniz Costa Passos3, Leila Azevedo1, Lucila Bizari Fernandes do Prado4, Regina Maria França Fernandes1.   

Abstract

OBJECTIVE: To estimate the prevalence of restless legs syndrome/Willis-Ekbom disease (RLS/WED) and its impact on sleep and quality of life in children and adolescents.
METHODS: This was a cross-sectional study conducted in the Municipality of Cássia dos Coqueiros, Brazil. Participants included 383 children and adolescents 5-17 years of age. A comparison group was randomly matched by gender and age with the RLS/WED-affected individuals, pairing one by one.
RESULTS: Interviews were conducted for 383 individuals by a neurologist experienced in sleep medicine. RLS/WED was diagnosed using the essential clinical criteria for definitive RLS/WED in children recommended by the International Restless Legs Syndrome Study Group. Sleep and quality of life were evaluated using the Sleep Behavior Questionnaire (SBQ) and the Health-related Quality of Life Questionnaire─Pediatric Quality of Life Inventory (PedsQL). Comparisons were established with a group of randomly selected individuals without RLS/WED, matched by age and gender (control group). The prevalence of RLS/WED symptoms that manifested at least twice a week was 1.9%. The average age of children with RLS/WED was higher compared to the general population (11.5 ± 2.3 vs 9.9 ± 2.5, p < 0.005). A family history of RLS/WED was detected in 90.9% of the patients. The scores obtained by SBQ were higher (53.9 ± 9.4 vs 47.6 ± 10.9, p < 0.047), whereas the scores achieved by PedsQL were lower (69.8 ± 14.8 vs 81.9 ± 10.4, p < 0.003) in children with RLS/WED compared to controls.
CONCLUSION: The prevalence of RLS/WED symptoms manifested at least twice in the preceding week was 1.9% in children and adolescents. Worsened sleep and quality of life were observed in the study.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Children; Epidemiology; Quality of life; Restless legs syndrome; Sleep quality; Willis-Ekbom disease

Mesh:

Year:  2016        PMID: 28215250     DOI: 10.1016/j.sleep.2016.10.014

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  6 in total

Review 1.  Update on Restless Legs Syndrome: from Mechanisms to Treatment.

Authors:  Paulina Gonzalez-Latapi; Roneil Malkani
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-27       Impact factor: 5.081

2.  Comparison of Subjective Sleep Quality of Long-Term Residents at Low and High Altitudes: SARAHA Study.

Authors:  Ravi Gupta; Jan Ulfberg; Richard P Allen; Deepak Goel
Journal:  J Clin Sleep Med       Date:  2018-01-15       Impact factor: 4.062

Review 3.  Tools for the Assessment of Pediatric Restless Legs Syndrome.

Authors:  Pamela Hamilton Stubbs; Arthur S Walters
Journal:  Front Psychiatry       Date:  2020-05-05       Impact factor: 4.157

4.  Association of Restless Legs Syndrome With Risk of Suicide and Self-harm.

Authors:  Sheng Zhuang; Muzi Na; John W Winkelman; Djibril Ba; Chun-Feng Liu; Guodong Liu; Xiang Gao
Journal:  JAMA Netw Open       Date:  2019-08-02

5.  Acupuncture and related techniques for restless legs syndrome: A protocol for systematic review and meta-analysis.

Authors:  Jie Xiang; Honglian Li; Jun Xiong; Fanghui Hua; Shouqiang Huang; Yunfeng Jiang; Hailiang Qiang; Fan Xie; Min Wang
Journal:  Medicine (Baltimore)       Date:  2020-09-25       Impact factor: 1.817

6.  Sleep and restless legs syndrome in female adolescents with idiopathic musculoskeletal pain.

Authors:  Rita Aparecida Ribeiro Amorim; Gustavo A Moreira; Flavia Heloisa Santos; Maria Teresa Terreri; Juliana Molina; Lívia de Freitas Keppeke; Simone Guerra Lopes da Silva; Melissa Mariti Fraga; Vanessa Bugni Miotto E Silva; Tufik Sergio; Claudio Arnaldo Len
Journal:  J Pediatr (Rio J)       Date:  2019-11-20       Impact factor: 2.990

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.